Total Payments
$5,135
2024 Payments
$2,471
Companies
15
Transactions
43
Medicare Patients
4,338
Medicare Billing
$3.0M
Payment Breakdown by Category
Food & Beverage$2,838 (55.3%)
Research$1,722 (33.5%)
Other$375.00 (7.3%)
Education$199.98 (3.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,838 | 30 | 55.3% |
| Unspecified | $1,722 | 8 | 33.5% |
| Honoraria | $375.00 | 3 | 7.3% |
| Education | $199.98 | 2 | 3.9% |
Payments by Type
General
$3,413
35 transactions
Research
$1,722
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $1,722 | 8 | $0 (2024) |
| Myriad Genetic Laboratories, Inc. | $778.54 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $679.81 | 6 | $0 (2023) |
| Seagen Inc. | $467.00 | 5 | $0 (2023) |
| Janssen Biotech, Inc. | $444.24 | 4 | $0 (2024) |
| Daiichi Sankyo Inc. | $272.69 | 2 | $0 (2024) |
| GlaxoSmithKline, LLC. | $122.40 | 1 | $0 (2021) |
| Averitas Pharma Inc. | $120.29 | 1 | $0 (2023) |
| CTI BioPharma Corp. | $117.24 | 1 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $107.63 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,471 | 15 | Regeneron Pharmaceuticals, Inc. ($1,722) |
| 2023 | $1,007 | 10 | AstraZeneca Pharmaceuticals LP ($246.91) |
| 2022 | $588.75 | 6 | AstraZeneca Pharmaceuticals LP ($198.92) |
| 2021 | $1,068 | 12 | Myriad Genetic Laboratories, Inc. ($269.19) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/22/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $501.93 | Research |
| Study: A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC • Category: ONCOLOGY | ||||||
| 08/22/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $310.20 | Research |
| Study: A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC • Category: ONCOLOGY | ||||||
| 08/22/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $101.24 | Research |
| Study: A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC • Category: ONCOLOGY | ||||||
| 08/22/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $97.75 | Research |
| Study: A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC • Category: ONCOLOGY | ||||||
| 08/22/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $83.86 | Research |
| Study: A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC • Category: ONCOLOGY | ||||||
| 08/22/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $80.10 | Research |
| Study: A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC • Category: ONCOLOGY | ||||||
| 08/21/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $149.96 | Research |
| Study: A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC • Category: ONCOLOGY | ||||||
| 07/22/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $396.96 | Research |
| Study: A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC • Category: ONCOLOGY | ||||||
| 06/12/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $33.82 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2024 | Janssen Biotech, Inc. | TALVEY (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $132.96 | General |
| Category: Oncology | ||||||
| 05/02/2024 | Myriad Genetic Laboratories, Inc. | PRECISETUMOR (Device) | Honoraria | In-kind items and services | $112.50 | General |
| Category: ONCOLOGY | ||||||
| 04/29/2024 | Myriad Genetic Laboratories, Inc. | PRECISETUMOR (Device) | Honoraria | In-kind items and services | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 03/13/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Honoraria | In-kind items and services | $112.50 | General |
| Category: ONCOLOGY | ||||||
| 02/22/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $107.60 | General |
| Category: ONCOLOGY | ||||||
| 01/12/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Education | In-kind items and services | $99.99 | General |
| Category: Oncology | ||||||
| 12/09/2023 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: Neuropsychiatry | ||||||
| 09/26/2023 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $100.53 | General |
| Category: ONCOLOGY | ||||||
| 08/08/2023 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $120.29 | General |
| Category: PAIN MANAGEMENT | ||||||
| 07/11/2023 | Seagen Inc. | — | Education | In-kind items and services | $99.99 | General |
| 06/20/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $120.29 | General |
| Category: Oncology | ||||||
| 05/16/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $17.04 | General |
| Category: Oncology | ||||||
| 04/27/2023 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $120.29 | General |
| Category: Oncology | ||||||
| 04/20/2023 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $117.24 | General |
| Category: Hematology | ||||||
| 03/16/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $126.62 | General |
| Category: Oncology | ||||||
| 02/28/2023 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $165.09 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC | Regeneron Pharmaceuticals, Inc. | $1,722 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 43 | 1,485 | 103,109 | $2.7M | $1.1M |
| 2022 | 47 | 1,667 | 155,589 | $3.8M | $1.6M |
| 2021 | 26 | 842 | 35,245 | $868,053 | $343,859 |
| 2020 | 14 | 344 | 542 | $106,963 | $28,555 |
Total Patients
4,338
Total Services
294,485
Medicare Billing
$3.0M
Procedure Codes
130
All Medicare Procedures & Services
130 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 14 | 9,800 | $862,400 | $376,451 | 43.7% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 14 | 6,120 | $483,480 | $232,882 | 48.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 58 | 10,680 | $341,760 | $182,593 | 53.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 43 | 27,501 | $165,006 | $64,632 | 39.2% |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 11 | 1,400 | $106,400 | $50,057 | 47.0% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 16 | 420 | $126,240 | $36,370 | 28.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 92 | 304 | $181,488 | $30,380 | 16.7% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 31 | 30,000 | $60,000 | $25,805 | 43.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 94 | 95 | $34,770 | $12,262 | 35.3% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 12 | 70 | $28,910 | $9,463 | 32.7% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 21 | 61 | $35,563 | $8,229 | 23.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 167 | 632 | $45,504 | $6,405 | 14.1% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 16 | 3,900 | $15,600 | $5,368 | 34.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 72 | 110 | $26,400 | $5,335 | 20.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 82 | 378 | $38,934 | $4,512 | 11.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $13,932 | $4,306 | 30.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 32 | 38 | $10,412 | $3,473 | 33.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 16 | 59 | $13,452 | $3,344 | 24.9% |
| 96409 | Administration of chemotherapy into vein using push technique | Office | 2023 | 15 | 41 | $17,302 | $3,261 | 18.8% |
| J0640 | Injection, leucovorin calcium, per 50 mg | Office | 2023 | 19 | 1,020 | $6,120 | $3,169 | 51.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 23 | 64 | $18,560 | $3,005 | 16.2% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 73 | 73 | $8,468 | $2,993 | 35.3% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 21 | 90 | $10,890 | $2,304 | 21.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 24 | 60 | $9,540 | $1,332 | 14.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 20 | 54 | $7,074 | $1,185 | 16.8% |
About Constance Gore, APN
Constance Gore, APN is a Acute Care healthcare provider based in Morristown, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235192139.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Constance Gore, APN has received a total of $5,135 in payments from pharmaceutical and medical device companies, with $2,471 received in 2024. These payments were reported across 43 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($2,838).
As a Medicare-enrolled provider, Gore has provided services to 4,338 Medicare beneficiaries, totaling 294,485 services with total Medicare billing of $3.0M. Data is available for 4 years (2020–2023), covering 130 distinct procedure/service records.
Ad
Practice Information
- Specialty Acute Care
- Location Morristown, NJ
- Active Since 04/11/2006
- Last Updated 09/26/2013
- Taxonomy Code 363LA2100X
- Entity Type Individual
- NPI Number 1235192139
Products in Payments
- LIBTAYO (Biological) $1,722
- TUKYSA (Drug) $367.01
- TAGRISSO (Drug) $362.90
- DARZALEX (Biological) $311.28
- myRisk (Device) $269.19
- PRECISETUMOR (Device) $262.50
- MYRISK (Device) $246.85
- TALVEY (Biological) $132.96
- LYNPARZA (Drug) $126.62
- ZEJULA (Drug) $122.40
- QUTENZA (Drug) $120.29
- Vonjo (Drug) $117.24
- REBLOZYL (Biological) $107.63
- Enhertu (Drug) $107.60
- PADCEV (Drug) $100.32
- VENCLEXTA (Drug) $96.08
- CALQUENCE (Drug) $78.63
- Cabometyx (Drug) $70.45
- INGREZZA (Drug) $19.66
- Lenvima (Drug) $17.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Acute Care Doctors in Morristown
Ms. Tina Occhiuto, Aprn, Bc, APRN, BC
Acute Care — Payments: $21,053
Acute Care $21,053
Mrs. Linda Suplicki, Rn, Msn, Apn, C, RN, MSN, APN, C
Acute Care — Payments: $11,898
Acute Care $11,898
Mrs. Karen English, Np, NP
Acute Care — Payments: $10,053
Acute Care $10,053
Morgan Bowden, Agacnp, AGACNP
Acute Care — Payments: $7,926
Acute Care $7,926
Mr. Jacqueline Fearon-Clarke, Nurse Practitioner, NURSE PRACTITIONER
Acute Care — Payments: $7,847
Acute Care $7,847
Cristina Valdez, Acnp-Bc, ACNP-BC
Acute Care — Payments: $6,955
Acute Care $6,955